A high-potency 2,000mg protocol that replaces what your cells stop making. NAD levels fall 50 to 70 percent by age 50, which is roughly when people start describing their energy as gone rather than low.
NAD is the coenzyme your mitochondria use to turn food into usable energy and to run DNA repair. Production falls steadily with age. Replenishing it supports essential energy production and works against the biological signs of aging.
You cannot train your way out of a supply problem. Most over-the-counter NAD products deliver a fraction of a clinical dose; ours is a 2,000mg protocol prescribed and monitored by a licensed provider.
A weekly B-12 MIC injection supporting energy, fat metabolism and recovery. It is the lowest-commitment protocol we offer and a common first step for members who want to feel a difference before committing to a longer program.
Frequently stacked with NAD+ or a GLP-1 protocol. Your provider will tell you whether that makes sense for you.
Dose and delivery. Most retail products supply precursors at a small fraction of a clinical dose. This is a prescribed 2,000mg protocol with provider oversight and quarterly labs.
Most patients report changes in energy and clarity within the first few weeks. Recovery and sleep effects tend to show up over one to three months. Results vary.
Frequently, yes. Many patients run NAD+ alongside GLP-1 or sermorelin. Your provider reviews interactions and sets the combined protocol.
No. NAD+ does not require a lab panel to begin. If you want a baseline anyway, or you are weighing NAD+ against a hormone protocol, start with Longevity Bloodwork instead.
What each protocol does, what it costs, what bloodwork it needs, and how to pick. Emailed once, no drip campaign. Your SPENGA50 code comes with it.
SPENGA has partnered with the best in medical wellness, Apex MD. Exclusive member access, physician-guided protocols, and $50 off your first month with code SPENGA50.
Pick the one that sounds most like you. We will point you at the right protocol and pre-fill your intake.